FINWIRES · TerminalLIVE
FINWIRES

Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says

By

Sagimet Biosciences (SGMT) is making "good progress" in advancing denifanstat as a treatment for moderate to severe acne for the US market, Wedbush Securities said in a note Tuesday.

The investment firm said positive data from studies conducted in China suggest limited clinical risk for the experimental therapy, which is expected to enter phase 3 testing in H2 after regulatory clearance.

The company expects fast patient enrollment in the phase 3 study, with topline data possible by the end of 2027 or in early 2028, according to the note.

Wedbush said Sagimet ended Q2 with $257.6 million in cash after raising $175 million in April, with its cash runway expected to extend through 2028 and beyond the anticipated denifanstat phase 3 readout.

The firm said recent investor discussions reinforced the view that Sagimet remains "deeply undervalued" and continues to offer significant upside despite recent share gains.

Wedbush Securities has an outperform rating on Sagimet Biosciences, with a price target of $28.

Price: $9.56, Change: $-0.01, Percent Change: -0.10%

Related Articles

Wire

Fermi Signs First Binding Lease Agreement at Project Matador in Texas; Shares Rise After Hours

Fermi (FRMI) said late Monday it has signed its first binding customer lease at its Project Matador campus in Texas, a deal expected to generate about $6.5 billion over its initial 15-year term for the first phase.The lease between Fermi's subsidiary Fermi Campus 1 and TensorWave TEX1, a unit of TensorWave, covers a facility supported by 222 megawatts of total power once the final delivery phase begins.The agreement includes expansion rights for two additional data centers that would bring the partnership to more than 650 MW if exercised.Project Matador's first power is targeted for 2026, with construction already underway and permits secured for about 6 GW of the planned 17-GW campus.Fermi shares jumped 19% in after-hours trading.

$FRMI
Wire

Everpure Secures Second Hyperscaler Design, Supply Agreement; Shares Rise After Hours

Everpure (P) secured a second design and supply contract with an undisclosed top-five hyperscaler.The first contract was announced in late 2024 and uses Everpure's advanced software-powered DirectFlash technology to optimize hyperscale storage.The latest contract will be a "significant contributor to future revenue" starting in fiscal 2028, the company said Monday in a statement.Everpure shares rose 7.7% in after-hours trading.

$P
Wire

Upwork Q2 Adjusted Earnings Rise, Revenue Declines; Shares Fall After-Hours

Upwork (UPWK) reported Q2 non-GAAP earnings late Monday of $0.41 per diluted share, up from $0.35 a year earlier.Analysts polled by FactSet expected $0.34.Revenue for the quarter ended June 30 was $191.7 million, down from $194.9 million a year earlier.Analysts expected $189.9 million.The company expects Q3 non-GAAP EPS of $0.31 to $0.33 on revenue of $176 million to $184 million. Analysts expect $0.41 and $193.8 million, respectively.The company now expects 2026 non-GAAP EPS of $1.38 to $1.43 on revenue of $730 million to $750 million. It previously expected non-GAAP EPS of $1.50 to $1.55 on revenue of $760 million to $790 million.Analysts expect $1.54 and $776.0 million, respectively.Upwork shares fell over 21% in after-hours trading.

$UPWK